Department of Neuroscience & Experimental Therapeutics, College of Medicine, Texas A&M Health Science Center, Bryan, TX 77807, United States.
Department of Neuroscience & Experimental Therapeutics, College of Medicine, Texas A&M Health Science Center, Bryan, TX 77807, United States.
Cytokine. 2022 Nov;159:156005. doi: 10.1016/j.cyto.2022.156005. Epub 2022 Sep 7.
The human heterozygous 15q13.3 microdeletion is associated with neuropathological disorders, most prominently with epilepsy and intellectual disability. The 1.5 Mb deletion encompasses six genes (FAN1 [MTMR15], MTMR10, TRPM1, KLF13, OTUD7A, and CHRNA7); all but one (TRPM1) are expressed in the brain. The 15q13.3 microdeletion causes highly variable neurological symptoms, and confounding factors may contribute to a more severe phenotype. CHRNA7 and KLF13 are involved in immune system regulation and altered immune responses may contribute to neurological deficits. We used the Df[h15q13]/+ transgenic mouse model with a heterozygous deletion of the orthologous region (Het) to test the hypothesis that the microdeletion increases innate immune responses compared to wild type (WT). Male and female mice were acutely challenged with the bacteriomimetic lipopolysaccharide (LPS, 0.1 mg/kg, i.p.) or the viral mimetic polyinosinic:polycytidylic acid (Poly(I:C), 5 mg/kg). Hippocampal mRNA expression of pro-inflammatory cytokines and chemokines were determined three hours after injection using quantitative PCR analysis. In controls, expression was not affected by sex or genotype. LPS and Poly(I:C) resulted in significantly increased hippocampal expression of cytokines, chemokines, and interferon-γ (IFNγ), with more robust increases for TNF-α, IL-6, IL-1β, CXCL1, and CCL2 by LPS, higher induction of IFNγ by Poly(I:C), and similar increases of CCL4 and CCL5 by both agents. Generally, Hets exhibited stronger responses than WT mice, and significant effects of genotype or genotype × treatment interactions were detected for CXCL1 and CCL5, and IL-6, IL-1β, and CCL4, respectively, after LPS. Sex differences were detected for some targets. LPS but not Poly(I:C), reduced overnight burrowing independent of sex or genotype, suggesting that LPS induced sickness behavior. Thus, mice carrying the microdeletion have an increased innate immune response following a LPS challenge, but further studies will have to determine the extent and mechanisms of altered immune activation and subsequent contributions to 15q13.3 microdeletion associated deficits.
人类杂合性 15q13.3 微缺失与神经病理学疾病有关,最突出的是癫痫和智力障碍。1.5Mb 的缺失包含六个基因(FAN1[MTMR15]、MTMR10、TRPM1、KLF13、OTUD7A 和 CHRNA7);除了一个(TRPM1)之外,所有这些基因都在大脑中表达。15q13.3 微缺失导致高度可变的神经症状,混杂因素可能导致更严重的表型。CHRNA7 和 KLF13 参与免疫系统调节,改变的免疫反应可能导致神经缺陷。我们使用杂合性缺失同源区域(Het)的 Df[h15q13]/+ 转基因小鼠模型来检验以下假说:与野生型(WT)相比,微缺失会增加固有免疫反应。雄性和雌性小鼠接受细菌模拟物脂多糖(LPS,0.1mg/kg,腹腔注射)或病毒模拟物聚肌胞苷酸(Poly(I:C),5mg/kg)的急性挑战。注射后三小时,使用定量 PCR 分析测定海马炎性细胞因子和趋化因子的 mRNA 表达。在对照组中,性别和基因型均不影响表达。LPS 和 Poly(I:C)导致海马细胞因子、趋化因子和干扰素-γ(IFNγ)的表达显著增加,LPS 导致 TNF-α、IL-6、IL-1β、CXCL1 和 CCL2 的增加更明显,Poly(I:C)导致 IFNγ 的诱导增加,两种药物均导致 CCL4 和 CCL5 的增加相似。通常,Het 表现出比 WT 小鼠更强的反应,并且在 LPS 后检测到基因型或基因型-治疗相互作用的显著影响CXCL1 和 CCL5,以及 IL-6、IL-1β 和 CCL4。一些靶点检测到性别差异。LPS 但不是 Poly(I:C),独立于性别或基因型减少了夜间挖掘,表明 LPS 诱导了疾病行为。因此,携带微缺失的小鼠在 LPS 挑战后固有免疫反应增加,但还需要进一步研究来确定改变的免疫激活的程度和机制,以及随后对 15q13.3 微缺失相关缺陷的贡献。